抗体导向酶药物疗法（ADEPT）：试验与磨难。

Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations.

机构信息

Research Department of Oncology, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK.

Department of Medical Oncology, Imperial College London, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.

出版信息

Adv Drug Deliv Rev. 2017 Sep 1;118:2-7. doi: 10.1016/j.addr.2017.09.009. Epub 2017 Sep 12.

DOI:10.1016/j.addr.2017.09.009

PMID:28916498

Abstract

Antibody directed enzyme prodrug therapy has the potential to be an effective therapy for most common solid cancers. Clinical studies with CPG2 system have shown the feasibility of this approach. The key limitation has been immunogenicity of the enzyme. Technologies now exist to eliminate this problem. Non-immunogenic enzymes in combination with prodrugs that generate potent cytotoxic drugs can provide a powerful approach to cancer therapy. ADEPT has the potential to be non -toxic to normal tissue and can therefore be combined with other modalities including immunotherapy for greater clinical benefit.

摘要

抗体导向酶药物前体疗法有可能成为治疗大多数常见实体瘤的有效方法。CPG2 系统的临床研究已经证明了这种方法的可行性。主要的限制因素一直是酶的免疫原性。现在已经有技术可以解决这个问题。与能够产生有效细胞毒素药物的前体药物结合使用的非免疫原性酶，可以为癌症治疗提供一种强大的方法。ADEPT 有可能对正常组织无毒，因此可以与其他方式结合使用，包括免疫疗法，以获得更大的临床益处。